The world leaders in cell and gene therapy.

Prof. Sir Peter Donnelly DPhil, FRS, FMedSci

CEO & Co-Founder · Genomics

CEO and co-founder of Genomics, translating insights from human genetics into better healthcare and drug discovery.

Dr. Edwin Stone PhD

CEO · Cellular Origins

Leads Cellular Origins, bringing advanced automation to cell-therapy manufacturing so promising treatments can be produced reliably at commercial scale.

Dr. Erik Wiklund PhD

CEO · Circio

Leads Circio’s work on circular RNA, building a platform designed to deliver durable, next-generation genetic medicines.

Dr. Miguel Forte MD, PhD

CEO · Kiji Therapeutics

An experienced cell-and-gene therapy executive leading Kiji Therapeutics and the development of next-generation immune medicines.

Kim Steel

Founder & Managing Director · SAPRO Consulting & CRO

A clinical-research leader with more than 18 years of experience across CRO, pharmaceutical and biotech organisations, directing first-in-human and Phase I–IV studies and founding SAPRO to give emerging biotechs a more flexible trial pathway partner.

Dr. Ricardo Baptista PhD

Chief Technology Officer · SmartCella

A biotechnology engineer specialising in cell and gene therapy CMC, focused on creating scalable, affordable manufacturing solutions for allogeneic cell therapies.

Dr. Ed Samuel PhD

Chief Operating Officer · Cell and Gene Therapy Catapult

An advanced-therapies operations leader responsible for CGT Catapult’s Manufacturing Innovation team and GMP facilities, with more than two decades of experience spanning development, tech transfer and scale-up.

Alexander Seyf

CEO · Autolomous

Dr. Michael Roberts PhD

CEO & Founder · Chromatin Bioscience

Founder of Chromatin Bioscience, which designs cell-type-selective synthetic promoters. Previously built Synpromics into a leading gene control company, acquired by AskBio in 2019.

Tamer Mohamed

Founder & CEO · Aspect Biosystems

Founded Aspect Biosystems, which bioprints tissue therapeutics designed to replace or repair tissue in the body.

Jon Ellis

CEO · Trenchant BioSystems

Dr. Marcos Burger Ramos PhD

CSO & Co-Founder · Anomer Bio

Dr. Stuart Lowe PhD

Head of Advanced Therapies · TTP PLC

Dr. Simon Boa PhD, MBA

Managing Director · Bramble Bio

Managing Director of Bramble Bio, a cell-therapy CDMO. More than 20 years of life-sciences leadership spanning commercialisation and market expansion at Thermo Fisher Scientific, Merck and Becton Dickinson, with a PhD in epigenetics from the Roslin Institute / University of Edinburgh and an MBA from Warwick.

Dr. Sławomir Jaros PhD, EMBA

CSO & CQO · ArThec

CSO, CQO and Management Board member at ArThec, where he leads scientific and strategic development of the PEARL tissue-engineering platform for cartilage regeneration. More than 20 years across research, GMP manufacturing and clinical development of biologics and advanced therapy medicinal products.

Dr. Kayleigh Thirlwell PhD

Senior Director · Resolution Therapeutics

Senior Director at Resolution Therapeutics, working on macrophage cell-therapy development and translational research. A PhD immunologist with more than a decade of experience taking cell therapies from research towards the clinic.

Dr. Shankar Musunuri PhD, MBA

Chairman, CEO & Co-founder · Ocugen

Chairman, CEO and co-founder of Ocugen, developing modifier gene therapies for blindness. A biotech operator with more than 30 years of experience, including nearly 15 years at Pfizer where he led global operations for Prevnar 13, and founding Nuron Biotech.

Prof. Chris Molloy

CEO · BioIndustry Association (BIA)

Chief Executive of the BIA, the trade association for the UK’s innovative life sciences and biotech industry. Previously the founding CEO of Medicines Discovery Catapult, with more than 30 years of UK and international life-sciences experience.

Dr. Gray Kueberuwa DPhil

CEO · ImmunoKey

CEO of ImmunoKey, a Manchester-area biotech developing a platform to unlock CAR T-cell therapy for solid cancers. Holds a DPhil in oncolytic virotherapy from the University of Oxford.

Prof. Sir Peter Donnelly DPhil, FRS, FMedSci

CEO & Co-Founder · Genomics

CEO and co-founder of Genomics, translating insights from human genetics into better healthcare and drug discovery.

Dr. Edwin Stone PhD

CEO · Cellular Origins

Leads Cellular Origins, bringing advanced automation to cell-therapy manufacturing so promising treatments can be produced reliably at commercial scale.

Dr. Erik Wiklund PhD

CEO · Circio

Leads Circio’s work on circular RNA, building a platform designed to deliver durable, next-generation genetic medicines.

Dr. Miguel Forte MD, PhD

CEO · Kiji Therapeutics

An experienced cell-and-gene therapy executive leading Kiji Therapeutics and the development of next-generation immune medicines.

Kim Steel

Founder & Managing Director · SAPRO Consulting & CRO

A clinical-research leader with more than 18 years of experience across CRO, pharmaceutical and biotech organisations, directing first-in-human and Phase I–IV studies and founding SAPRO to give emerging biotechs a more flexible trial pathway partner.

Dr. Ricardo Baptista PhD

Chief Technology Officer · SmartCella

A biotechnology engineer specialising in cell and gene therapy CMC, focused on creating scalable, affordable manufacturing solutions for allogeneic cell therapies.

Dr. Ed Samuel PhD

Chief Operating Officer · Cell and Gene Therapy Catapult

An advanced-therapies operations leader responsible for CGT Catapult’s Manufacturing Innovation team and GMP facilities, with more than two decades of experience spanning development, tech transfer and scale-up.

Alexander Seyf

CEO · Autolomous

Dr. Michael Roberts PhD

CEO & Founder · Chromatin Bioscience

Founder of Chromatin Bioscience, which designs cell-type-selective synthetic promoters. Previously built Synpromics into a leading gene control company, acquired by AskBio in 2019.

Tamer Mohamed

Founder & CEO · Aspect Biosystems

Founded Aspect Biosystems, which bioprints tissue therapeutics designed to replace or repair tissue in the body.

Jon Ellis

CEO · Trenchant BioSystems

Dr. Marcos Burger Ramos PhD

CSO & Co-Founder · Anomer Bio

Dr. Stuart Lowe PhD

Head of Advanced Therapies · TTP PLC

Dr. Simon Boa PhD, MBA

Managing Director · Bramble Bio

Managing Director of Bramble Bio, a cell-therapy CDMO. More than 20 years of life-sciences leadership spanning commercialisation and market expansion at Thermo Fisher Scientific, Merck and Becton Dickinson, with a PhD in epigenetics from the Roslin Institute / University of Edinburgh and an MBA from Warwick.

Dr. Sławomir Jaros PhD, EMBA

CSO & CQO · ArThec

CSO, CQO and Management Board member at ArThec, where he leads scientific and strategic development of the PEARL tissue-engineering platform for cartilage regeneration. More than 20 years across research, GMP manufacturing and clinical development of biologics and advanced therapy medicinal products.

Dr. Kayleigh Thirlwell PhD

Senior Director · Resolution Therapeutics

Senior Director at Resolution Therapeutics, working on macrophage cell-therapy development and translational research. A PhD immunologist with more than a decade of experience taking cell therapies from research towards the clinic.

Dr. Shankar Musunuri PhD, MBA

Chairman, CEO & Co-founder · Ocugen

Chairman, CEO and co-founder of Ocugen, developing modifier gene therapies for blindness. A biotech operator with more than 30 years of experience, including nearly 15 years at Pfizer where he led global operations for Prevnar 13, and founding Nuron Biotech.

Prof. Chris Molloy

CEO · BioIndustry Association (BIA)

Chief Executive of the BIA, the trade association for the UK’s innovative life sciences and biotech industry. Previously the founding CEO of Medicines Discovery Catapult, with more than 30 years of UK and international life-sciences experience.

Dr. Gray Kueberuwa DPhil

CEO · ImmunoKey

CEO of ImmunoKey, a Manchester-area biotech developing a platform to unlock CAR T-cell therapy for solid cancers. Holds a DPhil in oncolytic virotherapy from the University of Oxford.

Prof. Sir Peter Donnelly DPhil, FRS, FMedSci

CEO & Co-Founder · Genomics

CEO and co-founder of Genomics, translating insights from human genetics into better healthcare and drug discovery.

Dr. Edwin Stone PhD

CEO · Cellular Origins

Leads Cellular Origins, bringing advanced automation to cell-therapy manufacturing so promising treatments can be produced reliably at commercial scale.

Dr. Erik Wiklund PhD

CEO · Circio

Leads Circio’s work on circular RNA, building a platform designed to deliver durable, next-generation genetic medicines.

Dr. Miguel Forte MD, PhD

CEO · Kiji Therapeutics

An experienced cell-and-gene therapy executive leading Kiji Therapeutics and the development of next-generation immune medicines.

Kim Steel

Founder & Managing Director · SAPRO Consulting & CRO

A clinical-research leader with more than 18 years of experience across CRO, pharmaceutical and biotech organisations, directing first-in-human and Phase I–IV studies and founding SAPRO to give emerging biotechs a more flexible trial pathway partner.

Dr. Ricardo Baptista PhD

Chief Technology Officer · SmartCella

A biotechnology engineer specialising in cell and gene therapy CMC, focused on creating scalable, affordable manufacturing solutions for allogeneic cell therapies.

Dr. Ed Samuel PhD

Chief Operating Officer · Cell and Gene Therapy Catapult

An advanced-therapies operations leader responsible for CGT Catapult’s Manufacturing Innovation team and GMP facilities, with more than two decades of experience spanning development, tech transfer and scale-up.

Alexander Seyf

CEO · Autolomous

Dr. Michael Roberts PhD

CEO & Founder · Chromatin Bioscience

Founder of Chromatin Bioscience, which designs cell-type-selective synthetic promoters. Previously built Synpromics into a leading gene control company, acquired by AskBio in 2019.

Tamer Mohamed

Founder & CEO · Aspect Biosystems

Founded Aspect Biosystems, which bioprints tissue therapeutics designed to replace or repair tissue in the body.

Jon Ellis

CEO · Trenchant BioSystems

Dr. Marcos Burger Ramos PhD

CSO & Co-Founder · Anomer Bio

Dr. Stuart Lowe PhD

Head of Advanced Therapies · TTP PLC

Dr. Simon Boa PhD, MBA

Managing Director · Bramble Bio

Managing Director of Bramble Bio, a cell-therapy CDMO. More than 20 years of life-sciences leadership spanning commercialisation and market expansion at Thermo Fisher Scientific, Merck and Becton Dickinson, with a PhD in epigenetics from the Roslin Institute / University of Edinburgh and an MBA from Warwick.

Dr. Sławomir Jaros PhD, EMBA

CSO & CQO · ArThec

CSO, CQO and Management Board member at ArThec, where he leads scientific and strategic development of the PEARL tissue-engineering platform for cartilage regeneration. More than 20 years across research, GMP manufacturing and clinical development of biologics and advanced therapy medicinal products.

Dr. Kayleigh Thirlwell PhD

Senior Director · Resolution Therapeutics

Senior Director at Resolution Therapeutics, working on macrophage cell-therapy development and translational research. A PhD immunologist with more than a decade of experience taking cell therapies from research towards the clinic.

Dr. Shankar Musunuri PhD, MBA

Chairman, CEO & Co-founder · Ocugen

Chairman, CEO and co-founder of Ocugen, developing modifier gene therapies for blindness. A biotech operator with more than 30 years of experience, including nearly 15 years at Pfizer where he led global operations for Prevnar 13, and founding Nuron Biotech.

Prof. Chris Molloy

CEO · BioIndustry Association (BIA)

Chief Executive of the BIA, the trade association for the UK’s innovative life sciences and biotech industry. Previously the founding CEO of Medicines Discovery Catapult, with more than 30 years of UK and international life-sciences experience.

Dr. Gray Kueberuwa DPhil

CEO · ImmunoKey

CEO of ImmunoKey, a Manchester-area biotech developing a platform to unlock CAR T-cell therapy for solid cancers. Holds a DPhil in oncolytic virotherapy from the University of Oxford.

Dr. Angela Kukula PhD, MBA

Director of Science and Innovation · Populate

Director of Science and Innovation at Populate, with experience spanning academia, the NHS and the commercial sector.

Steve Bates OBE, FMedSci

Executive Chair, Office for Life Sciences · UK Government

A leading voice for UK life sciences, connecting government, industry and investors to strengthen the country’s health-innovation ecosystem.

Dr. Sven Kili MBChB, MRCS

Partner · Saisei Ventures

A physician, biotech operator and investor helping advanced-therapy companies turn ambitious science into scalable, patient-ready businesses.

Prof. Farzin Farzaneh PhD, FRCPath, FRSB

CSO of ViroCell & Professor at King's College London · ViroCell

A translational scientist and company builder advancing viral-vector manufacturing and the clinical delivery of cell and gene therapies.

Lisa Deschamps MBA

CEO · AviadoBio

Chief Executive Officer and Executive Board Member at AviadoBio. Previously Senior Vice President and Chief Business Officer of Novartis Gene Therapies, where she led worldwide commercialisation across its gene therapy portfolio.

Dr. Carolyn Porter PhD, MBA

Chief Business Officer · Cell and Gene Therapy Catapult

A biotech leader with more than 25 years of experience across academia, technology transfer, university spin-outs and the biopharmaceutical industry.

Dr. Stephen Sullivan PhD, MBA

Founder & Managing Director · Lindville Bio

A stem-cell scientist and ATMP consultant with more than two decades of experience helping pluripotent stem-cell therapies move from early research towards scalable, regulatory-ready manufacture.

Alexa Crăciunescu

Director & Founding Member · Act for Hope

A founding member of Act for Hope, the foundation bringing the cell and gene therapy community together to speed therapies to patients.

Dr. Gaurav Shah MD

CEO · Rocket Pharmaceuticals

Leads Rocket Pharmaceuticals, developing gene therapies for rare and devastating diseases.

Dr. Hans Schambye MD, PhD

CEO · BOOST Pharma

Mike Klein

CEO · Genomenon

Dr. Ali Pashazadeh MBBS, MRCS, MBA

Partner · Tree Hill Partners

Dr. Stuart Curbishley PhD

Chief Development & Manufacturing Officer · adthera bio

Dr. Lindsay Davies PhD

CEO of QVance & CSO of NextCell Pharma · QVance

CEO of QVance, a quality-control analytics provider specialising in ATMPs, and CSO of NextCell Pharma, a clinical-stage mesenchymal stromal cell therapy company. 25 years in advanced therapies across the British, German, Finnish and Swedish ecosystems, and European VP Elect of the International Society for Cell & Gene Therapy.

Dr. Léon Spijkers PhD

CEO · Korecyte Bio

Co-founder and CEO of Korecyte Bio, developing next-generation CAR-based cellular immunotherapies for solid tumours. More than 15 years in life-sciences management, R&D and business development, with a PhD in molecular cell biology.

Dr. Killian Hanlon PhD

CEO & Chief Scientist · Lir Therapeutics

Co-founder, CEO and Chief Scientist of Lir Therapeutics, an AI viral-vector company engineering AAV capsids for dose reduction, tissue targeting and immune evasion. A former Harvard Medical School postdoctoral fellow with more than a decade of AAV engineering experience and multiple patents in the field.

Dr. Devyn Smith PhD

CEO · Arbor Biotechnologies

CEO of Arbor Biotechnologies, a gene-editing company developing genetic medicines. A cell-and-gene therapy leader with more than 20 years of experience, previously COO and Head of Strategy at Sigilon Therapeutics and COO of Pfizer’s UK-based Neusentis unit.

Dr. Marion Hitchcock PhD

Managing Director, Gene & Cell Therapies Incubator · Bayer

Managing Director of Bayer’s Gene & Cell Therapies Incubator in Berlin, supporting European cell-and-gene therapy start-ups on the path from science to the clinic.

Jason Foster MBA

CEO & Executive Director · Ori Biotech

Chief Executive Officer and Executive Director of Ori Biotech, which builds manufacturing systems for cell and gene therapies. He has spent more than 20 years building consulting, pharma and technology companies, including Indivior, which listed on the London Stock Exchange in a £2.5 billion exit in 2014.

Dr. Angela Kukula PhD, MBA

Director of Science and Innovation · Populate

Director of Science and Innovation at Populate, with experience spanning academia, the NHS and the commercial sector.

Steve Bates OBE, FMedSci

Executive Chair, Office for Life Sciences · UK Government

A leading voice for UK life sciences, connecting government, industry and investors to strengthen the country’s health-innovation ecosystem.

Dr. Sven Kili MBChB, MRCS

Partner · Saisei Ventures

A physician, biotech operator and investor helping advanced-therapy companies turn ambitious science into scalable, patient-ready businesses.

Prof. Farzin Farzaneh PhD, FRCPath, FRSB

CSO of ViroCell & Professor at King's College London · ViroCell

A translational scientist and company builder advancing viral-vector manufacturing and the clinical delivery of cell and gene therapies.

Lisa Deschamps MBA

CEO · AviadoBio

Chief Executive Officer and Executive Board Member at AviadoBio. Previously Senior Vice President and Chief Business Officer of Novartis Gene Therapies, where she led worldwide commercialisation across its gene therapy portfolio.

Dr. Carolyn Porter PhD, MBA

Chief Business Officer · Cell and Gene Therapy Catapult

A biotech leader with more than 25 years of experience across academia, technology transfer, university spin-outs and the biopharmaceutical industry.

Dr. Stephen Sullivan PhD, MBA

Founder & Managing Director · Lindville Bio

A stem-cell scientist and ATMP consultant with more than two decades of experience helping pluripotent stem-cell therapies move from early research towards scalable, regulatory-ready manufacture.

Alexa Crăciunescu

Director & Founding Member · Act for Hope

A founding member of Act for Hope, the foundation bringing the cell and gene therapy community together to speed therapies to patients.

Dr. Gaurav Shah MD

CEO · Rocket Pharmaceuticals

Leads Rocket Pharmaceuticals, developing gene therapies for rare and devastating diseases.

Dr. Hans Schambye MD, PhD

CEO · BOOST Pharma

Mike Klein

CEO · Genomenon

Dr. Ali Pashazadeh MBBS, MRCS, MBA

Partner · Tree Hill Partners

Dr. Stuart Curbishley PhD

Chief Development & Manufacturing Officer · adthera bio

Dr. Lindsay Davies PhD

CEO of QVance & CSO of NextCell Pharma · QVance

CEO of QVance, a quality-control analytics provider specialising in ATMPs, and CSO of NextCell Pharma, a clinical-stage mesenchymal stromal cell therapy company. 25 years in advanced therapies across the British, German, Finnish and Swedish ecosystems, and European VP Elect of the International Society for Cell & Gene Therapy.

Dr. Léon Spijkers PhD

CEO · Korecyte Bio

Co-founder and CEO of Korecyte Bio, developing next-generation CAR-based cellular immunotherapies for solid tumours. More than 15 years in life-sciences management, R&D and business development, with a PhD in molecular cell biology.

Dr. Killian Hanlon PhD

CEO & Chief Scientist · Lir Therapeutics

Co-founder, CEO and Chief Scientist of Lir Therapeutics, an AI viral-vector company engineering AAV capsids for dose reduction, tissue targeting and immune evasion. A former Harvard Medical School postdoctoral fellow with more than a decade of AAV engineering experience and multiple patents in the field.

Dr. Devyn Smith PhD

CEO · Arbor Biotechnologies

CEO of Arbor Biotechnologies, a gene-editing company developing genetic medicines. A cell-and-gene therapy leader with more than 20 years of experience, previously COO and Head of Strategy at Sigilon Therapeutics and COO of Pfizer’s UK-based Neusentis unit.

Dr. Marion Hitchcock PhD

Managing Director, Gene & Cell Therapies Incubator · Bayer

Managing Director of Bayer’s Gene & Cell Therapies Incubator in Berlin, supporting European cell-and-gene therapy start-ups on the path from science to the clinic.

Jason Foster MBA

CEO & Executive Director · Ori Biotech

Chief Executive Officer and Executive Director of Ori Biotech, which builds manufacturing systems for cell and gene therapies. He has spent more than 20 years building consulting, pharma and technology companies, including Indivior, which listed on the London Stock Exchange in a £2.5 billion exit in 2014.

Dr. Angela Kukula PhD, MBA

Director of Science and Innovation · Populate

Director of Science and Innovation at Populate, with experience spanning academia, the NHS and the commercial sector.

Steve Bates OBE, FMedSci

Executive Chair, Office for Life Sciences · UK Government

A leading voice for UK life sciences, connecting government, industry and investors to strengthen the country’s health-innovation ecosystem.

Dr. Sven Kili MBChB, MRCS

Partner · Saisei Ventures

A physician, biotech operator and investor helping advanced-therapy companies turn ambitious science into scalable, patient-ready businesses.

Prof. Farzin Farzaneh PhD, FRCPath, FRSB

CSO of ViroCell & Professor at King's College London · ViroCell

A translational scientist and company builder advancing viral-vector manufacturing and the clinical delivery of cell and gene therapies.

Lisa Deschamps MBA

CEO · AviadoBio

Chief Executive Officer and Executive Board Member at AviadoBio. Previously Senior Vice President and Chief Business Officer of Novartis Gene Therapies, where she led worldwide commercialisation across its gene therapy portfolio.

Dr. Carolyn Porter PhD, MBA

Chief Business Officer · Cell and Gene Therapy Catapult

A biotech leader with more than 25 years of experience across academia, technology transfer, university spin-outs and the biopharmaceutical industry.

Dr. Stephen Sullivan PhD, MBA

Founder & Managing Director · Lindville Bio

A stem-cell scientist and ATMP consultant with more than two decades of experience helping pluripotent stem-cell therapies move from early research towards scalable, regulatory-ready manufacture.

Alexa Crăciunescu

Director & Founding Member · Act for Hope

A founding member of Act for Hope, the foundation bringing the cell and gene therapy community together to speed therapies to patients.

Dr. Gaurav Shah MD

CEO · Rocket Pharmaceuticals

Leads Rocket Pharmaceuticals, developing gene therapies for rare and devastating diseases.

Dr. Hans Schambye MD, PhD

CEO · BOOST Pharma

Mike Klein

CEO · Genomenon

Dr. Ali Pashazadeh MBBS, MRCS, MBA

Partner · Tree Hill Partners

Dr. Stuart Curbishley PhD

Chief Development & Manufacturing Officer · adthera bio

Dr. Lindsay Davies PhD

CEO of QVance & CSO of NextCell Pharma · QVance

CEO of QVance, a quality-control analytics provider specialising in ATMPs, and CSO of NextCell Pharma, a clinical-stage mesenchymal stromal cell therapy company. 25 years in advanced therapies across the British, German, Finnish and Swedish ecosystems, and European VP Elect of the International Society for Cell & Gene Therapy.

Dr. Léon Spijkers PhD

CEO · Korecyte Bio

Co-founder and CEO of Korecyte Bio, developing next-generation CAR-based cellular immunotherapies for solid tumours. More than 15 years in life-sciences management, R&D and business development, with a PhD in molecular cell biology.

Dr. Killian Hanlon PhD

CEO & Chief Scientist · Lir Therapeutics

Co-founder, CEO and Chief Scientist of Lir Therapeutics, an AI viral-vector company engineering AAV capsids for dose reduction, tissue targeting and immune evasion. A former Harvard Medical School postdoctoral fellow with more than a decade of AAV engineering experience and multiple patents in the field.

Dr. Devyn Smith PhD

CEO · Arbor Biotechnologies

CEO of Arbor Biotechnologies, a gene-editing company developing genetic medicines. A cell-and-gene therapy leader with more than 20 years of experience, previously COO and Head of Strategy at Sigilon Therapeutics and COO of Pfizer’s UK-based Neusentis unit.

Dr. Marion Hitchcock PhD

Managing Director, Gene & Cell Therapies Incubator · Bayer

Managing Director of Bayer’s Gene & Cell Therapies Incubator in Berlin, supporting European cell-and-gene therapy start-ups on the path from science to the clinic.

Jason Foster MBA

CEO & Executive Director · Ori Biotech

Chief Executive Officer and Executive Director of Ori Biotech, which builds manufacturing systems for cell and gene therapies. He has spent more than 20 years building consulting, pharma and technology companies, including Indivior, which listed on the London Stock Exchange in a £2.5 billion exit in 2014.